Text Size

Functional Proteomics of Alveolar Macrophages

This study has been completed.
Sponsor:
Information provided by:
Ohio State University
ClinicalTrials.gov Identifier:
NCT00806091
First received: December 9, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted
  Purpose

The purpose of this study is to obtain young white blood cells (monocytes) from the investigators donated blood for research into how these cells change into large, mature white blood cells (macrophages) and how smoking causes Chronic Obstructive Pulmonary Disease (COPD).


Condition
COPD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Functional Proteomics of Alveolar Macrophages

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • to define AM's pathogenic pathways underlying the development of COPD [ Time Frame: end of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • to determine protein polymorphism(s) that impact genetic susceptibility to COPD [ Time Frame: end of study ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

blood BAL fluid breathe condensation saliva


Enrollment: 72
Study Start Date: July 2004
Study Completion Date: December 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
COPD subjects
healthy subjects

Detailed Description:

Our research goal is to identify new targets and strategies to help care for patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic airway inflammatory disorder characterized by a progressive loss of pulmonary function. Mononuclear phagocytes are known to be critically involved in both repair/remodeling and destructive events in COPD. Although smoking is the chief environmental risk factor for COPD, the molecular details responsible for the genesis and progression of smoking-mediated COPD require further investigation. In searching for new knowledge and research strategies for this challenging topic, we have made substantial progress in mononuclear phagocyte proteomics and laid the groundwork for this translational research of COPD.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

smokers with and without COPD, general population

Criteria

Inclusion Criteria:

  • COPD, smoker
  • COPD, non smoker

Exclusion Criteria:

  • none
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00806091

Locations
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University
Investigators
Principal Investigator: Haifeng Wu, MD Ohio State University
  More Information

No publications provided

Responsible Party: Haifeng Wu, The Ohio State University
ClinicalTrials.gov Identifier: NCT00806091     History of Changes
Other Study ID Numbers: 2004H0102
Study First Received: December 9, 2008
Last Updated: December 9, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Ohio State University:
AM proteomes will be compared between smokers with and without COPD

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on June 18, 2013